WooGene B&G Co., Ltd (KOSDAQ:018620)

South Korea flag South Korea · Delayed Price · Currency is KRW
693.00
-21.00 (-2.94%)
At close: Mar 9, 2026
-21.43%
Market Cap 20.02B
Revenue (ttm) 54.77B
Net Income (ttm) -6.11B
Shares Out 28.89M
EPS (ttm) -212.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 125,286
Average Volume 573,359
Open 700.00
Previous Close 714.00
Day's Range 673.00 - 709.00
52-Week Range 668.00 - 1,046.00
Beta 0.36
RSI 32.78
Earnings Date Mar 20, 2026

About WooGene B&G

WooGene B&G Co., Ltd. engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. It offers antibiotic, vaccine, nutrient, anti-inflammation, metabolic stimulant, and iron supplement products for swine, poultry, cattle, aquatic animals, companion animals, and raw materials, as well as operates vaccine research center. The company was formerly known as WooJin Co., Ltd. and changed its name to WooGene B&G Co., Ltd. in March 2001. WooGene B&G Co., Ltd. was founded in 1977 and is headquartered in Hw... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 92
Stock Exchange KOSDAQ
Ticker Symbol 018620
Full Company Profile

Financial Performance

In 2024, WooGene B&G's revenue was 55.68 billion, a decrease of -3.87% compared to the previous year's 57.92 billion. Losses were -5.22 billion, 341.0% more than in 2023.

Financial Statements

News

There is no news available yet.